Indication
Vanishing White Matter Disease
2 clinical trials
2 products
Product
ABBV-CLS-7262Clinical trial
A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy Following ABBV-CLS-7262 Administration in Adult and Pediatric Subjects With Vanishing White Matter DiseaseStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Longitudinal Study of Neurodegenerative DisordersStatus: Recruiting, Estimated PCD: 2030-01-01